nach oben

Erschienen in:

24.01.2018 | Original Research

Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?

verfasst von: Mohammed Azeez Alzaidi, Hossein Ali Arab, Saeid Amanpour, Reza Shirkoohi, Samad Muhammadnejad, Farhang Sasani

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Some epidemiological studies have shown an association between opium consumption and the incidence of gastrointestinal (GI) cancer. The present study was designed to investigate the effects of opium on the initiation of GI cancer in rats.

Methods

Forty-five rats were randomly divided into three groups; each received different treatment for 40 weeks. The rats in group 1 received purified water, while animals in group 2 were treated with 5 mg/kg diethylnitrosamine (DEN) orally for 8 weeks and continued with purified water by the end of the experiment. The third experimental group received 300 mg/kg opium for 16 weeks and then continued with 50 mg/kg phenobarbital by the end of the 40th week. The growth of tumors in the treated groups was assessed by histological changes and the up/down expression of p53, cdkn1, cdk2, e-cdh, and n-cdh genes in different parts of GI tract.

Results

Histological examinations revealed that DEN was able to induce the growth of tumor in GI tract as shown by active mitotic figure in different regions of GI system and hyperplasia of hepatocytes associated with infiltration of inflammatory cells, intestinal villous hypertrophy, and colorectal adenoma. There was also significant (p < 0.05) overexpression of p53, cdk2, and n-Cdh genes in different parts of digestive system in DEN-treated group. However, these pathological changes and the degradation of gene expression were not observed in the opium-treated group.

Conclusion

The results of this study suggest that the opium does not promote the initiation of cancer in GI tract.

Sadjadi A, Nouraie M, Mohagheghi MA, Mousavi-Jarrahi A, Malekezadeh R, Parkin DM. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev. 2005;6(3):359–63.PubMed

American Cancer Society. Cancer facts and figures. Atlanta, GA: Publisher American cancer Society. 2012. http://www.cancer.org/research/cancerfactfigures/cancer-facts-figure-2012:1-2.

Liao DJ, Blanck A, Eneroth P, Gustafsson JA, Hällström IP. Diethylnitrosamine causes pituitary damage, disturbs hormone levels, and reduces sexual dimorphism of certain liver functions in the rat. Environ Health Perspect. 2001;109(9):943–7. https://doi.org/10.1289/ehp.01109943.CrossRefPubMedPubMedCentral

Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther. 1996;71(1):57–81. https://doi.org/10.1016/0163-7258(96)00062-9.CrossRefPubMed

Aggrawal A. Opium: the king of narcotics. In: Aggrawal A, editor. Narcotic drugs. New Delhi: New Delhi National Book Trust; 1995. p. 161.

United Nations Office on Drugs and Crime (UNODC). World drug report 2010. United Nations Publication Sales No.10.XI.13; 2010:1–50.

Heydari M, Hashem Hashempur M, Zargaran A. Medicinal aspects of opium as described in Avicenna’s Canon of Medicine. Acta Medico-Historica Adriatica. 2013;11(1):101–12.PubMed

Shakeri R, Kamangar F, Nasrollahzadeh D, Nouraie M, Khademi H, Etemadi A, et al. Is opium a real risk factor for esophageal cancer or just a methodological artifact? Hospital and neighborhood controls in case-control studies. PLoS One. 2012;7(3):e32711. https://doi.org/10.1371/journal.pone.0032711.CrossRefPubMedPubMedCentral

Malekzadeh MM, Khademi H, Pourshams A, Etemadi A, Poustchi H, Bagheri M, et al. Opium use and risk of mortality from digestive diseases: a prospective cohort study. Am J Gastroenterol. 2013;108(11):1757–65. https://doi.org/10.1038/ajg.2013.336.CrossRefPubMedPubMedCentral

10.

Shakeri R, Malekzadeh R, Etemadi A, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al. Opium: an emerging risk factor for gastric adenocarcinoma. Int J Cancer. 2013;133(2):455–61. https://doi.org/10.1002/ijc.28018.CrossRefPubMed

11.

Mousavi MRA, Damghani MA, Haghdoust AA, Khamesipour A. Opium and risk of laryngeal cancer. Laryngoscope. 2003;113(11):1939–43.CrossRefPubMed

12.

Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R, Semnani S, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50 000 adults in Iran. BMJ. 2012;344(apr17 2):e2502. https://doi.org/10.1136/bmj.e2502.CrossRefPubMedPubMedCentral

13.

Hosseini SY, Safarinejad MR, Amini E, Hooshyar H. Opium consumption and risk of bladder cancer: a case-control analysis. In: Urologic Oncology: Seminars and Original Investigations. Elsevier; 2010. vol 6, p. 610–616.

14.

Dillenburg CF, Kruel CDP, Cerski CT, Edelweiss MI, Schier AS. Morphine does no promote esophageal carcinogenesis in rats exposed to diethylnitrosamine. Arq Gastroenterol. 2008;45(1):87–92. https://doi.org/10.1590/S0004-28032008000100016.CrossRefPubMed

15.

Tegeder I, Grösch S, Schmidtko A, Häussler A, Schmidt H, Niederberger E, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells. Cancer Res. 2003;63(8):1846–52.PubMed

16.

Sasamura T, Nakamura S, Iida Y, Fujii H, Murata J, Saiki I, et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 2002;441(3):185–91. https://doi.org/10.1016/S0014-2999(02)01450-4.CrossRefPubMed

17.

Aneja R, Zhou J, Zhou B, Chandra R, Joshi HC. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice. Mol Cancer Ther. 2006;5(9):2366–77. https://doi.org/10.1158/1535-7163.MCT-06-0205.CrossRefPubMed

18.

Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2008;63(1):117–26. https://doi.org/10.1007/s00280-008-0720-z.CrossRefPubMed

19.

Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 2008;67(8):3862–70.CrossRef

20.

Sajadian S, Vatankhah M, Majdzadeh M, Kouhsari SM, Ghahremani MH, Ostad SN. Cell cycle arrest and apoptogenic properties of opium alkaloids noscapine and papaverine on breast cancer stem cells. Toxicol Mech Methods. 2015;25(5):388–95. https://doi.org/10.3109/15376516.2015.1045656.CrossRefPubMed

21.

Hayes AW, Kruger CL. Hayes’ principles and methods of toxicology. Boca Raton: CRC Press; 2014.

22.

Lijinsky W. Chemistry and biology of N-nitroso compounds. Cambridge: Cambridge University Press; 1992.

23.

Sánchez-Pérez Y, Carrasco-Legleu C, García-Cuellar C, Pérez-Carreón J, Hernández-García S, Salcido-Neyoy M, et al. Oxidative stress in carcinogenesis. Correlation between lipid peroxidation and induction of preneoplastic lesions in rat hepatocarcinogenesis. Cancer Lett. 2005;217(1):25–32. https://doi.org/10.1016/j.canlet.2004.07.019.CrossRefPubMed

24.

Schmahl D. Combination effects in chemical carcinogenesis. In: Chambers PL, Klinger W, editors. Further studies in the assessment of toxic actions. Arch Toxicol Suppl. 1980;4:29–40.

25.

Lijinsky W. Intestinal cancer induced by N-nitroso compounds. Toxicol Pathol. 1988;16(2):198–204. https://doi.org/10.1177/019262338801600212.CrossRefPubMed

26.

Kawanishi S, Hiraku Y, Murata M, Oikawa S. The role of metals in site-specific DNA damage with reference to carcinogenesis 1, 2. Free Radic Biol Med. 2002;32(9):822–32. https://doi.org/10.1016/S0891-5849(02)00779-7.CrossRefPubMed

27.

Valko M, Rhodes C, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1–40. https://doi.org/10.1016/j.cbi.2005.12.009.CrossRefPubMed

28.

Pawan M, Choudhary R, Mathur R, Choudhary M, Kamla M. Study on harmful effects of opium on liver and lungs in chronic opium addicts of western Rajasthan. Journal of Bangladesh Society of Physiologist. 2011;6(2):122–6.

29.

Atici S, Cinel I, Cinel L, Doruk N, Eskandari G, Oral U. Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. J Biosci. 2005;30(2):245–52. https://doi.org/10.1007/BF02703705.CrossRefPubMed

30.

Frenklakh L, Bhat RS, Bhaskaran M, Sharma S, Sharma M, Dinda A, et al. Morphine-induced degradation of the host defense barrier. Dig Dis Sci. 2006;51(2):318–25. https://doi.org/10.1007/s10620-006-3132-0.CrossRefPubMed

31.

Harari Y, Weisbrodt NW, Moody FG. The effect of morphine on mast cell–mediated mucosal permeability. Surgery. 2006;139(1):54–60. https://doi.org/10.1016/j.surg.2005.07.009.CrossRefPubMed

32.

Aylon Y, Oren M. New plays in the p53 theater. Curr Opin Genet Dev. 2011;21(1):86–92. https://doi.org/10.1016/j.gde.2010.10.002.CrossRefPubMed

33.

El-Deiry W. P21/P53, cellular growth control and genomic integrity. Cyclin Dependent Kinase (CDK) Inhibitors. In: Current Topics in Microbiology and Immunology book series. 1998;227:121–137.

34.

Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400–14. https://doi.org/10.1038/nrc2657.CrossRefPubMedPubMedCentral

35.

Zhu W, Abbas T, Dutta A. DNA Replication and Genomic. Genomic Advances in Experimental Medicine and Biology book series. 2005; 249–279.

36.

Pasz-Walczak G, Kordek R, Faflik M. P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. Pathology-Research and Practice. 2001;197(10):683–9. https://doi.org/10.1078/0344-0338-00146.CrossRef

37.

Sotillo R, Dubus P, Martn J, de la Cueva E, Ortega S, Malumbres M, et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 2001;20(23):6637–47. https://doi.org/10.1093/emboj/20.23.6637.CrossRefPubMedPubMedCentral

38.

Doak S, Jenkins G, Parry E, Griffiths A, Shah V, Baxter J, et al. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer. 2003;89(9):1729–35. https://doi.org/10.1038/sj.bjc.6601323.CrossRefPubMedPubMedCentral

Titel: Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?
verfasst von: Mohammed Azeez Alzaidi
Hossein Ali Arab
Saeid Amanpour
Reza Shirkoohi
Samad Muhammadnejad
Farhang Sasani
Publikationsdatum: 24.01.2018
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 2/2018
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-017-0050-7

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Opium Consumption and the Incidence of Cancer: Does Opium Account as an Emerging Risk Factor for Gastrointestinal Cancer?

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Long-Term Survival with Chemoradiation Alone in Locally Advanced Unresectable Gallbladder Cancer: First Case Report of a New Paradigm

Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort

Small Bowel Obstruction Secondary to Ileal Mucosa-Associated Lymphoid Tissue Lymphoma

Synchronous Adenocarcinomas of Pancreatic Body and Gastro-Esophageal Junction: Management Strategy

Rapid Development of Omentum Metastasis Following Stereotactic Body Radiotherapy (Sbrt) to Para-Aortic Lymph Nodes from Colon Cancer

Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie